Danone steps up health focus to boost growth
Targets like-for-like sales growth of 3-5% in 2025-2028
Sets long-term ambition for 3 bln euros free-cash flow
Health, Medical Nutrition key growth drivers
Shares fall amid some disappointment targets not more ambitious
Adds share reaction, analyst comment
By Dominique Vidalon and Agata Rybska
PARIS, June 20 (Reuters) -French food group Danone DANO.PA will step up its focus on health and medical nutrition as it seeks to grow sales and boost cash generation from 2025 to 2028, the company said on Thursday.
The maker of Activia yoghurt, Evian water and Aptamil baby food expects to achieve annual like-for-like net sales growth of 3-5% for that period, in line with the target it set for 2024.
That should allow Danone to deliver a double-digit return on invested capital (ROIC) and progress towards its long-term free cash flow target of 3 billion euros ($3.2 billion), it said ahead of a presentation to investors in Amsterdam.
Danone shares were down 3.5% in morning trade, with some analysts disappointed the targets were not more ambitious
"There was nothing in there really that would make people say 'Oh my God, this gives us new confidence'," Bernstein's Bruno Monteyne said.
"The two new and improved targets about free cash flow and ROIC are not exactly very challenging, and investors were hoping for more momentum behind the turnaround story" he added.
Robert Schramm-Fuchs, portfolio manager at Janus Henderson Investors, told Reuters on Monday the expectation was for Danone to keep targets unchanged from the ones it set for 2022-2024.
CEO Antoine de Saint-Affrique has attempted to stabilize Danone's sales and build more predictable revenues since taking the helm in 2021.
The company plans to diversify, making itself less reliant on its yoghurt and water brands while tapping into what it sees as a "tipping point" in the food industry where "health, and the role food plays in health, will become more critical than ever."
This would include scaling up, and seeking more acquisitions, in medical nutrition, de Saint-Affrique said.
($1 = 0.9334 euros)
Reporting by Dominique Vidalon, Agata Rybska; Editing by Michael Perry and Mark Potter
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
